Merck & Co., Inc. (MRK)
NYSE: MRK · Real-Time Price · USD
78.56
+0.96 (1.24%)
At close: Sep 26, 2025, 4:00 PM EDT
78.66
+0.10 (0.13%)
After-hours: Sep 26, 2025, 7:59 PM EDT
Merck & Co. Employees
As of December 31, 2024, Merck & Co. had 75,000 total employees, including 73,000 full-time and 2,000 part-time employees. The number of employees increased by 3,000 or 4.17% compared to the previous year.
Employees
75,000
Change (1Y)
3,000
Growth (1Y)
4.17%
Revenue / Employee
$848,213
Profits / Employee
$218,747
Market Cap
196.23B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 75,000 | 3,000 | 4.17% |
Dec 31, 2023 | 72,000 | 3,000 | 4.35% |
Dec 31, 2022 | 69,000 | 1,000 | 1.47% |
Dec 31, 2021 | 68,000 | -6,000 | -8.11% |
Dec 31, 2020 | 74,000 | 3,000 | 4.23% |
Dec 31, 2019 | 71,000 | 2,000 | 2.90% |
Dec 31, 2018 | 69,000 | 0 | - |
Dec 31, 2017 | 69,000 | 1,000 | 1.47% |
Dec 31, 2016 | 68,000 | 0 | - |
Dec 31, 2015 | 68,000 | -2,000 | -2.86% |
Dec 31, 2014 | 70,000 | -6,000 | -7.89% |
Dec 31, 2013 | 76,000 | -7,000 | -8.43% |
Dec 31, 2012 | 83,000 | -3,000 | -3.49% |
Dec 31, 2011 | 86,000 | -8,000 | -8.51% |
Dec 31, 2010 | 94,000 | -6,000 | -6.00% |
Dec 31, 2009 | 100,000 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
AbbVie | 55,000 |
MRK News
- 2 days ago - Merck: Game-Changing Oncology Drugs Power Stock Surge - Seeking Alpha
- 3 days ago - Merck: 25% Total Return CAGR Potential - Seeking Alpha
- 5 days ago - Variational AI Enters Collaboration with Merck to Apply Generative AI to Drug Discovery - Business Wire
- 6 days ago - Merck: Undervalued Pharma Stock With Defensive Approach And Compelling Dividend Yield - Seeking Alpha
- 8 days ago - Undercovered Dozen: Applied Digital, Merck, B2Gold And More - Seeking Alpha
- 9 days ago - FDA Approves Merck's KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) Injection for Subcutaneous Use in Adults Across Most Solid Tumor Indications for KEYTRUDA® (pembrolizumab) - Business Wire
- 9 days ago - US FDA approves Merck's new injectable version of Keytruda - Reuters
- 9 days ago - EMA committee recommends approval for injectable version of Merck's Keytruda - Reuters